Specialty medicines • Bangladesh

Tizaro (Tirzepatide)

Product Name : Tizaro
Generic Name : Tirzepatide
Formulation : Subcutaneous Injection (Pre-filled Syringe)
Available Pack Size : 1 Pre-filled Syringe per box
Available Strengths : 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
Manufacturer : Ziska Pharmaceuticals
Country Of Origin : Bangladesh

SKU tirzepatide-tizaro Categories , Brand:

Confirm your order

Speak with our team about your prescribed strength, pack size, price and delivery.
Use medicines only as prescribed by your clinician.

Description

Tizaro (Tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, a once-weekly subcutaneous injectable twincretin that simultaneously activates the GIP receptor (GIPR) with potency comparable to native GIP and the GLP-1 receptor (GLP-1R) to potentiate glucose-dependent insulin secretion from pancreatic beta cells, suppress inappropriate glucagon release from pancreatic alpha cells, slow gastric emptying to attenuate postprandial glucose excursions, and engage central satiety circuits in the hypothalamus, producing clinically meaningful reductions in both HbA1c and body weight that exceed those of any previously approved incretin-based agent.

 

Supplied as a subcutaneous injection in a pre-filled syringe, 1 pre-filled syringe per box, available in the complete approved strength range of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, and manufactured by Ziska Pharmaceuticals Ltd., Bangladesh. Its active ingredient, tirzepatide INN, is a 39-amino acid acylated peptide with structural homology to native GIP, engineered to bind and activate both GIPR and GLP-1R within a single molecular entity the first approved dual incretin receptor agonist (twincretin) in the antidiabetic drug class, structurally and mechanistically distinct from monoagonist GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide) that activate only the GLP-1 receptor.

 

The co-activation of GIPR by tirzepatide augments the GLP-1R-mediated glycemic and weight effects by engaging adipose tissue GIP receptors involved in lipid partitioning and by potentiating pancreatic beta cell responsiveness through synergistic cyclic adenosine monophosphate (cAMP) signaling from both receptor pathways simultaneously. In the pivotal SURPASS-1 monotherapy trial (478 patients, 40 weeks), tirzepatide 15 mg achieved a mean HbA1c reduction of 2.07% from baseline versus 0.04% with placebo, with 93.1% of patients achieving HbA1c below 7.0% versus 19.9% with placebo. In the SURPASS-2 head-to-head trial versus semaglutide 1 mg (1,879 patients, 40 weeks), tirzepatide 15 mg achieved superior HbA1c reduction of 2.37% versus 1.86% and body weight reduction of 11.2 kg versus 5.7 kg with semaglutide 1 mg establishing tirzepatide 15 mg as the most efficacious approved injectable antidiabetic agent in a prospective randomized active-controlled head-to-head trial.

 

Tizaro is the only Bangladeshi tirzepatide product supplying the full six-strength escalation range from 2.5 mg through 15 mg in a single Ziska Pharmaceuticals product line, enabling endocrinologists to advance patients through every approved dose step without changing supplier or formulation. Searching for Tizaro Tirzepatide? Mediaid Pharmacy lists this product across its diabetes medicines and Tirzepatide Medicines portfolios and ships it worldwide.

Basic Product Information of Tizaro (Tirzepatide)

Brand Name Tizaro (Tirzepatide)
Product Name Tizaro
Generic Name Tirzepatide INN
Drug Class Dual GIP/GLP-1 Receptor Agonist; Twincretin; Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonist; Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist; Dual Incretin Receptor Agonist; Once-Weekly Subcutaneous Injectable Antidiabetic Agent; Incretin Mimetic; Glucose-Dependent Insulin Secretion Potentiator; Glucagon Suppressor; Cardiometabolic Agent; Antiobesity Agent (Adjunct in T2DM)
Formulation Subcutaneous Injection (Pre-filled Syringe)
Available Strengths 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg tirzepatide per pre-filled syringe the complete six-step approved escalation range in a single Ziska Pharmaceuticals product line
Available Pack Size 1 pre-filled syringe per box
Recommended Dose & Administration Initiation dose (Weeks 1–4): 2.5 mg subcutaneously once weekly for 4 weeks. This is a tolerability initiation dose, not a therapeutic maintenance dose; it minimizes nausea and gastrointestinal adverse effects during treatment commencement. Step 1 First Therapeutic Dose (Weeks 5 onward): Increase to 5 mg subcutaneously once weekly after completing 4 weeks at 2.5 mg. Maintain 5 mg for at least 4 weeks before considering further escalation. Step 2: If additional glycemic control is required and 5 mg is tolerated, increase to 7.5 mg subcutaneously once weekly for at least 4 weeks. Step 3: If further escalation is required, increase to 10 mg subcutaneously once weekly for at least 4 weeks. Step 4: If additional control is still required, increase to 12.5 mg subcutaneously once weekly for at least 4 weeks. Step 5 Maximum Approved Dose: 15 mg subcutaneously once weekly. The 15 mg strength is the maximum approved tirzepatide dose and is available in the Tizaro range from Ziska Pharmaceuticals. This complete six-strength range distinguishes Tizaro from competing tirzepatide products that cover only the lower escalation steps. Injection sites: Administer subcutaneously into the abdomen (at least 5 cm from the navel), thigh, or upper arm; rotate injection sites with each weekly dose to reduce local injection site reactions. Tizaro may be injected at any time of day, with or without food. Missed dose: If a dose is missed and the next scheduled dose is more than 4 days away, administer the missed dose as soon as possible and resume the regular weekly schedule. If the next scheduled dose is 4 days or fewer away, skip the missed dose and continue with the next scheduled weekly injection. Do not administer two doses within 3 days of each other. Renal and hepatic impairment: No dose adjustment is required for mild to moderate renal impairment (eGFR 30 mL/min/1.73 m² or greater); use with caution in severe renal impairment. No dose adjustment required for hepatic impairment. Always confirm the dose, injection technique, and escalation schedule with the prescribing endocrinologist before initiating or adjusting Tizaro therapy.
Primary Indications Type 2 Diabetes Mellitus (T2DM): As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, used as monotherapy or in combination with other antidiabetic agents (metformin, sulfonylurea, SGLT2 inhibitor) or basal insulin when existing therapy does not achieve adequate glycemic control. Tirzepatide is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. Each treatment decision must account for baseline HbA1c, body weight goals, cardiovascular risk, concomitant antidiabetic medications, renal function, and gastrointestinal tolerability. Always consult the full prescribing information and the treating endocrinologist or diabetologist before initiating or adjusting therapy.
Manufacturer Ziska Pharmaceuticals Ltd., Bangladesh
Country of Origin Bangladesh
SKU tirzepatide-tizaro
Categories Diabetes Medicines; Tirzepatide Medicines
Storage Conditions Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze; discard Tizaro pre-filled syringes that have been frozen. If necessary, each pre-filled syringe may be stored unrefrigerated at room temperature up to 30°C (86°F) for a maximum of 21 days. Protect from light and direct heat. Keep in the original packaging until use. Keep out of the reach of children. Do not use after the expiry date printed on the carton and pre-filled syringe label.
Registration Bangladesh
Originator Reference Brand Mounjaro® (tirzepatide injection, developed and marketed by Eli Lilly and Company; approved by the U.S. Food and Drug Administration on May 13, 2022, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus). Mounjaro® contains tirzepatide INN as the active pharmaceutical ingredient in the same dual GIP/GLP-1 receptor agonist (twincretin) drug class. Tizaro is manufactured by Ziska Pharmaceuticals Ltd. in Bangladesh and is supplied through Mediaid Pharmacy for international procurement in all six approved strengths from 2.5 mg through 15 mg.
Global Supplier Mediaid Pharmacy, Worldwide Shipping Available

How Tizaro (Tirzepatide) Works: Dual GIP and GLP-1 Receptor Agonism and Twincretin Pharmacology in Type 2 Diabetes

Tirzepatide INN is a 39-amino acid acylated peptide that functions as a dual agonist at two distinct incretin hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). This dual receptor mechanism the first of its kind among approved antidiabetic agents earns tirzepatide the designation “twincretin.” Tizaro (Tirzepatide), manufactured by Ziska Pharmaceuticals Ltd. in Bangladesh, simultaneously activates two complementary glucose-lowering and weight-reducing signaling pathways that monoagonist GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide) cannot replicate.

GLP-1 is secreted by intestinal L cells in the distal ileum and colon following nutrient ingestion, stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon secretion from pancreatic alpha cells, slowing gastric emptying to reduce postprandial glucose excursions, and activating hypothalamic and brainstem satiety circuits. GIP is secreted by K cells in the duodenum and proximal jejunum in response to fat and carbohydrate ingestion, potentiating glucose-dependent insulin secretion through a distinct cAMP signaling cascade in pancreatic beta cells and engaging adipose tissue GIPR-expressing cells involved in lipid partitioning and energy balance. In type 2 diabetes mellitus (T2DM), both incretin axes are functionally impaired: the GLP-1 response is markedly attenuated and the residual GIP response fails to elicit a normal insulin secretory response in the insulin-resistant beta cell.

This is precisely the dual incretin deficit that tirzepatide’s co-receptor engagement addresses by simultaneously reconstituting both GIP and GLP-1 signaling arms within a single molecular entity. Tizaro supplies tirzepatide INN across the complete approved strength range 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg pre-filled syringes covering every dose step from tolerability initiation through the maximum approved 15 mg therapeutic dose.

The structural basis of tirzepatide’s dual receptor activity lies in its peptide architecture: a 39-amino acid sequence with structural homology to native GIP at the N-terminus, optimized through amino acid substitutions for balanced GIPR and GLP-1R binding affinity, conjugated at lysine-26 to a C20 fatty diacid moiety via a gamma-glutamic acid-miniPEG linker. This modification confers high albumin binding exceeding 99%, protects the peptide from N-terminal DPP-4 cleavage that inactivates native GIP and GLP-1 within 1 to 2 minutes of portal entry, and provides an extended elimination half-life of approximately 5 days that supports once-weekly subcutaneous dosing.

Tirzepatide activates GIPR with potency approximately equivalent to native GIP and activates GLP-1R with approximately 5-fold lower potency than native GLP-1, yet produces GLP-1R-mediated pharmacological effects (insulin secretion, glucagon suppression, gastric emptying delay, appetite suppression, body weight reduction) that equal or exceed those of optimized GLP-1 monoagonists at corresponding doses in head-to-head clinical trials. These superior outcomes are driven by receptor co-stimulation synergy, adipose tissue GIPR contributions to energy balance, and tissue-level interactions between the two simultaneously activated signaling pathways.

At the 15 mg maximum dose available in Tizaro and delivered through the Ziska Pharmaceuticals pre-filled syringe tirzepatide produced the highest HbA1c and body weight reductions recorded in any Phase 3 antidiabetic drug program: 2.37% mean HbA1c reduction and 11.2 kg mean weight loss versus semaglutide 1 mg in SURPASS-2, and 2.07% HbA1c reduction with 93.1% of patients achieving HbA1c below 7.0% as monotherapy in SURPASS-1.

Pharmacokinetically, following subcutaneous administration, tirzepatide reaches peak plasma concentration (Tmax) at approximately 8 to 72 hours, achieves steady-state concentrations by 4 weeks of once-weekly dosing, and is eliminated primarily via proteolytic degradation of the peptide backbone and fatty acid beta-oxidation, with no single dominant cytochrome P450 (CYP) metabolic pathway and no clinically relevant accumulation with weekly dosing across a broad range of renal and hepatic function. For the complete range of injectable antidiabetic medicines at Mediaid Pharmacy, browse the full portfolio for worldwide shipping.

Tizaro (Tirzepatide): Indications, Dosing, and Key Safety Information

Approved Indications Type 2 Diabetes Mellitus (T2DM): Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Tizaro (Tirzepatide) is used as monotherapy when other oral agents are not tolerated or are contraindicated, and as add-on combination therapy with metformin, sulfonylureas, SGLT2 inhibitors, or basal insulin when single-agent or existing combination therapy fails to achieve adequate HbA1c targets. Tirzepatide is not indicated for type 1 diabetes mellitus or diabetic ketoacidosis. The treating endocrinologist determines appropriate candidacy, dose titration schedule, and combination regimen based on individual patient HbA1c targets, weight goals, cardiovascular risk, renal function, and gastrointestinal tolerability profile.
Full Dosing Schedule Weeks 1–4 (Initiation): 2.5 mg subcutaneously once weekly. Tolerability initiation dose not the therapeutic maintenance dose; designed to minimize GI adverse effects. Weeks 5 onward Step 1: 5 mg subcutaneously once weekly for at least 4 weeks. First therapeutic maintenance dose. Step 2 (if required): 7.5 mg subcutaneously once weekly for at least 4 weeks. Step 3 (if required): 10 mg subcutaneously once weekly for at least 4 weeks. At this dose, tirzepatide achieved 2.10% mean HbA1c reduction and 9.3 kg weight loss versus semaglutide 1 mg in SURPASS-2. Step 4 (if required): 12.5 mg subcutaneously once weekly for at least 4 weeks. Step 5 Maximum Approved Dose: 15 mg subcutaneously once weekly. At 15 mg, tirzepatide achieved 2.37% HbA1c reduction and 11.2 kg weight loss versus semaglutide 1 mg in SURPASS-2. All six strengths are available in Tizaro from Ziska Pharmaceuticals. Inject subcutaneously into the abdomen, thigh, or upper arm; rotate injection sites each week. Administer at any time of day, with or without meals.
Common Adverse Reactions The most commonly reported adverse reactions with tirzepatide in the SURPASS Phase 3 clinical trial program are gastrointestinal: nausea (12 to 18% at 5 mg, increasing to 18 to 22% at 15 mg), diarrhea (12 to 17%), vomiting (5 to 11%), and constipation (6 to 11%), predominantly occurring during dose initiation and escalation phases and generally transient. The 2.5 mg initiation dose protocol embedded in the Tizaro dosing schedule is specifically designed to reduce the frequency and severity of these gastrointestinal effects during the first 4 weeks of treatment. The step-wise 4-week escalation intervals between each dose step allow further GI adaptation before each increase. Injection site reactions (erythema, pain, bruising) are reported in approximately 3 to 7% of patients. Hypoglycemia does not occur with Tizaro as monotherapy due to its strictly glucose-dependent insulin secretion mechanism; hypoglycemia risk increases when tirzepatide is combined with a sulfonylurea or basal insulin, and dose reduction of the sulfonylurea or insulin should be considered at treatment initiation. Rare serious adverse reactions include acute pancreatitis (discontinue Tizaro immediately if suspected), severe hypersensitivity reactions including anaphylaxis and angioedema, and acute gallbladder disease (cholelithiasis, cholecystitis). Tizaro (Tirzepatide) carries a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity data; it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Always discuss the complete safety profile with the treating endocrinologist before initiating or continuing Tizaro therapy.
Drug Interactions Oral medications requiring rapid absorption or with narrow therapeutic index: Tirzepatide delays gastric emptying and may reduce the peak plasma concentration (Cmax) and alter the time to peak concentration (Tmax) of concomitantly administered oral medications. Particular caution is warranted with narrow therapeutic index oral drugs such as warfarin, cyclosporine, and digoxin. Oral contraceptives: When initiating Tizaro or escalating the dose, gastric emptying delay may transiently reduce peak concentrations of oral contraceptives; switch to non-oral contraception or add a barrier method for 4 weeks after starting Tizaro and for 4 weeks after each dose escalation step. Warfarin and other vitamin K antagonists: Monitor INR more frequently when initiating or dose-escalating Tizaro due to the potential effect on warfarin absorption kinetics. Insulin secretagogues and basal insulin: Concomitant use with a sulfonylurea or basal insulin increases hypoglycemia risk; consider reducing the sulfonylurea or insulin dose when adding Tizaro to existing antidiabetic therapy. Other GLP-1 receptor agonists: Do not combine Tizaro (Tirzepatide) with another GLP-1 receptor agonist (semaglutide, liraglutide, dulaglutide, exenatide) as additive receptor agonism provides no established additional glycemic benefit and compounds gastrointestinal adverse effects.
Contraindications Tizaro (Tirzepatide) is contraindicated in: patients with a personal or family history of medullary thyroid carcinoma (MTC); patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); patients with known serious hypersensitivity to tirzepatide or any component of the Tizaro formulation (including anaphylaxis or angioedema). Tirzepatide is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
Renal Impairment No dose adjustment of Tizaro (Tirzepatide) is required for mild to moderate renal impairment (eGFR 30 mL/min/1.73 m² or greater). Use with caution in severe renal impairment (eGFR less than 30 mL/min/1.73 m²) due to limited clinical data; the predominantly non-renal elimination of tirzepatide means pharmacokinetic exposure is not substantially increased by renal impairment, but gastrointestinal adverse effects (nausea, vomiting, diarrhea) may precipitate dehydration and acute kidney injury in renally vulnerable patients, necessitating closer clinical monitoring, hydration counseling, and renal function assessment during dose initiation and each escalation step. Consult the treating endocrinologist and nephrologist for individualized guidance in patients with advanced chronic kidney disease.
Pregnancy & Lactation Tizaro (Tirzepatide) is not recommended during pregnancy. Tirzepatide caused adverse embryo-fetal developmental effects in animal reproductive toxicity studies at clinically relevant exposures; adequate and well-controlled human data in pregnancy are not available. Women of childbearing potential should use effective contraception throughout Tizaro therapy; if pregnancy occurs or is planned, discontinue Tizaro and transition to insulin therapy immediately under endocrinologist guidance. Breastfeeding is not recommended during Tizaro treatment, as it is unknown whether tirzepatide is excreted in human breast milk; the risk to the nursing infant cannot be excluded.

Who Should Use Tizaro (Tirzepatide)?

Tizaro (Tirzepatide) is indicated for adults with type 2 diabetes mellitus requiring improved glycemic control as an adjunct to diet and exercise a patient population defined by progressive insulin secretory failure, marked GLP-1 and GIP response impairment, postprandial glucagon excess, and frequently co-occurring excess body weight. These are patients for whom a once-weekly dual incretin receptor agonist provides simultaneous glycemic and cardiometabolic benefits that are mechanistically unachievable by existing oral antidiabetic classes or monoagonist injectable agents. The defining procurement advantage of Tizaro over all competing Bangladeshi tirzepatide products is the availability of all six approved strengths 2.5 mg through 15 mg within a single Ziska Pharmaceuticals product line, enabling endocrinologists to advance patients through every approved escalation step without switching supplier, formulation, or product brand.

First, adults with type 2 diabetes requiring substantial HbA1c reduction represent the primary clinical population where tirzepatide’s full dose range is most relevant. In SURPASS-1 monotherapy (40 weeks, 478 patients), the progression from 5 mg (1.87% HbA1c reduction) through 10 mg (1.89%) to 15 mg (2.07%) demonstrates that each escalation step provides additional glycemic benefit for patients not at target. Tizaro’s availability at 10 mg, 12.5 mg, and 15 mg doses unavailable in competing Bangladeshi tirzepatide products capped at 7.5 mg allows endocrinologists to prescribe the strengths where tirzepatide’s superiority over semaglutide is most pronounced.

Second, adults with type 2 diabetes and significant overweight or obesity for whom concurrent meaningful weight loss is a clinical priority alongside glycemic control benefit most at higher tirzepatide doses. In SURPASS-2 versus semaglutide 1 mg (40 weeks), tirzepatide 15 mg produced mean body weight reduction of 11.2 kg nearly double the 5.7 kg achieved with semaglutide 1 mg with a difference that was statistically significant (p<0.001). This weight reduction magnitude is available only at Tizaro’s 15 mg strength.

Third, adults with type 2 diabetes for whom existing GLP-1 monoagonist therapy (semaglutide, liraglutide) has produced suboptimal glycemic or weight outcomes benefit from tirzepatide’s additional GIPR co-agonism a mechanistically distinct pathway that monoagonist GLP-1 agents cannot engage.

Fourth, adults with type 2 diabetes for whom minimizing hypoglycemia risk is a clinical priority benefit from tirzepatide’s glucose-dependent mechanism, which produced no hypoglycemia as monotherapy across every SURPASS trial and across all six dose levels. Endocrinology centers co-sourcing Tizaro alongside other specialty injectable antidiabetic medicines can browse the Mediaid Pharmacy diabetes medicine collection for the full selection available for international delivery.

Global Supplier: Mediaid Pharmacy Worldwide Shipping for Tizaro (Tirzepatide)

Mediaid Pharmacy is a Dhaka-based supplier of specialty diabetes, endocrinology, and metabolic medicines with worldwide shipping to patients, diabetes specialist centers, endocrinology clinics, hospital pharmacy departments, and international distributors across all regions. Tizaro (Tirzepatide), manufactured by Ziska Pharmaceuticals Ltd. in Bangladesh, is supplied as a subcutaneous injection in pre-filled syringes, available in six strengths 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg 1 pre-filled syringe per box, with pricing quotations, stock confirmation, full product documentation, and end-to-end international delivery tracking for every order. The complete six-strength range of Tizaro covering the 2.5 mg tolerability initiation dose through the 5 mg and 7.5 mg first and second therapeutic steps, and extending to the 10 mg, 12.5 mg, and 15 mg higher escalation steps where tirzepatide’s superiority over semaglutide is clinically most significant provides endocrinology programs and diabetes specialist centers with the flexibility to source the entire approved tirzepatide escalation schedule from a single Ziska Pharmaceuticals product.

The pre-filled syringe formulation of Tizaro supports once-weekly self-administration without requiring dose measurement, device assembly, or needle attachment beyond the pre-filled unit, making procurement, dispensing, patient instruction, and injection technique training straightforward for diabetes clinics and endocrinology programs co-sourcing injectable antidiabetic therapy across diverse patient populations. Diabetes specialist centers managing type 2 diabetes, endocrinology programs requiring a dual GIP/GLP-1 receptor agonist with the full SURPASS Phase 3 clinical evidence base at all approved doses, hospital pharmacy departments co-sourcing injectable antidiabetic agents, international distributors, and individual patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all inquiries regarding Tizaro Tirzepatide stock availability, current pricing, and international delivery timelines. Procurement teams co-sourcing Tizaro with other specialty diabetes medicines can browse the complete buy diabetes medicines online catalog and the Ziska Pharmaceuticals medicines portfolio before requesting a consolidated quotation.

Why Choose Tizaro (Tirzepatide) from Mediaid Pharmacy?

Tizaro (Tirzepatide) delivers the most clinically documented HbA1c reduction and body weight reduction among all approved injectable antidiabetic agents, a differentiation established in the SURPASS clinical trial program through the unique twincretin mechanism of simultaneous GIP and GLP-1 receptor co-activation that no single-receptor GLP-1 agonist, DPP-4 inhibitor, SGLT2 inhibitor, or insulin class member can replicate in a single weekly injection. In SURPASS-2 (1,879 adults with type 2 diabetes, 40 weeks), tirzepatide 15 mg produced mean HbA1c reduction of 2.37% versus 1.86% with semaglutide 1 mg, and mean body weight reduction of 11.2 kg versus 5.7 kg with semaglutide 1 mg statistically significant superiority (p<0.001 for both endpoints) over the most widely prescribed GLP-1 receptor agonist in a prospective, randomized, active-controlled head-to-head trial. This 15 mg clinical advantage is only accessible through products that supply the maximum approved dose, and Tizaro is that product in the Ziska Pharmaceuticals tirzepatide range.

Tizaro’s complete six-strength pre-filled syringe range (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg), manufactured by Ziska Pharmaceuticals Ltd. in Bangladesh, is the primary procurement advantage over all competing Bangladeshi tirzepatide formulations that supply only the lower escalation steps: endocrinologists can advance patients through every approved dose escalation step from tolerability initiation at 2.5 mg through the maximum therapeutic dose at 15 mg without requiring a change of product, supplier, or formulation, supporting continuity of care, simplified pharmacy inventory management, and uninterrupted dose-escalation protocols for diabetes clinics sourcing injectable antidiabetic therapy internationally.

From a tolerability architecture perspective, the mandatory 2.5 mg initiation dose embedded in Tizaro’s approved dosing schedule reduces gastrointestinal adverse event-related treatment discontinuation compared to initiating directly at therapeutic doses, and the 4-week minimum interval at each escalation step allows progressive GI adaptation through the full six-step dose range.

The absence of hypoglycemia as monotherapy a direct consequence of tirzepatide’s strictly glucose-dependent insulin secretion mechanism means Tizaro can be initiated at any dose step without hypoglycemia dietary restriction protocols or additional blood glucose monitoring schedules beyond standard diabetic care.

From a dosing convenience standpoint, the once-weekly subcutaneous injection schedule eliminates the daily injection burden of liraglutide and the daily oral medication adherence requirement of DPP-4 inhibitors and SGLT2 inhibitors, supporting high adherence profiles in working-age patients, elderly patients, and all populations who benefit from weekly rather than daily medication routines. To source the full range of Ziska Pharmaceuticals medicines and the complete selection of tirzepatide injection products at Mediaid Pharmacy, browse both portfolios and contact the team for a personalized quotation.

Frequently Asked Questions About Tizaro (Tirzepatide)

What is Tizaro (Tirzepatide) used for?

Tizaro (Tirzepatide) is a dual GIP and GLP-1 receptor agonist a twincretin used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Administered once weekly as a subcutaneous injection, Tizaro is used as monotherapy when metformin or other oral agents are not tolerated or are contraindicated, and as add-on combination therapy with metformin, sulfonylureas, SGLT2 inhibitors, or basal insulin when existing treatment fails to achieve adequate HbA1c control. Tizaro (Tirzepatide) works by simultaneously activating the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R), stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing inappropriate glucagon release, slowing gastric emptying to reduce postprandial glucose excursions, and engaging central satiety pathways to reduce appetite and body weight. The originator brand for tirzepatide is Mounjaro® (Eli Lilly and Company, FDA-approved May 13, 2022 for adults with T2DM). Tizaro, manufactured by Ziska Pharmaceuticals Ltd. in Bangladesh, is available through Mediaid Pharmacy in all six approved strengths from 2.5 mg through 15 mg, with worldwide shipping to patients, diabetes specialist centers, and endocrinology clinics globally.

What is the generic name of Tizaro?

The generic name of Tizaro is tirzepatide INN. Tizaro is the brand name registered by Ziska Pharmaceuticals Ltd. for tirzepatide manufactured in Bangladesh. Tizaro is formulated as a subcutaneous injection in pre-filled syringes, available in six strengths 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg supplied as 1 pre-filled syringe per box, supporting the complete approved once-weekly dosing schedule from tolerability initiation at 2.5 mg through escalation to the maximum approved dose of 15 mg as directed by the treating endocrinologist. The originator reference brand is Mounjaro® (Eli Lilly and Company). Mediaid Pharmacy distributes Tizaro globally with worldwide shipping to patients, diabetes centers, endocrinology clinics, and hospital pharmacy departments.

What is the difference between Tizaro (Tirzepatide) and Mounjaro® (Tirzepatide)?

Tizaro and Mounjaro® both contain tirzepatide INN as the active pharmaceutical ingredient and share the same dual GIP/GLP-1 receptor agonist (twincretin) mechanism of action for type 2 diabetes mellitus. Mounjaro® is the originator brand developed and marketed by Eli Lilly and Company, approved by the FDA on May 13, 2022. Tizaro is manufactured by Ziska Pharmaceuticals Ltd. in Bangladesh and is supplied in pre-filled syringes across the complete six-strength range 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg covering every approved dose escalation step of the tirzepatide dosing schedule, with 1 pre-filled syringe per box, available through Mediaid Pharmacy for international procurement by specialist diabetes centers and patients in regions where Mounjaro® may be unavailable or cost-prohibitive. For the full range of buy tirzepatide online at Mediaid Pharmacy, browse the complete collection.

What are the available strengths of Tizaro Tirzepatide?

Tizaro (Tirzepatide) manufactured by Ziska Pharmaceuticals Ltd. is available in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg pre-filled syringes, supplied as 1 pre-filled syringe per box. The 2.5 mg strength is used for the 4-week tolerability initiation phase. The 5 mg strength is the first therapeutic maintenance dose. The 7.5 mg strength is the second escalation step. The 10 mg, 12.5 mg, and 15 mg strengths are the third, fourth, and fifth escalation steps respectively, with 15 mg being the maximum approved tirzepatide dose. This complete six-strength range distinguishes Tizaro from other Bangladeshi tirzepatide products that supply only the lower 2.5 mg to 7.5 mg steps. For ordering and stock availability, contact Mediaid Pharmacy at +8801773428128 or email info@mediaidpharmacy.com.

How is Tizaro (Tirzepatide) administered?

Tizaro (Tirzepatide) is administered once weekly as a subcutaneous injection using the pre-filled syringe. Recommended injection sites are the abdomen (at least 5 cm from the navel), the thigh, or the upper arm; rotate injection sites with each weekly administration to minimize local injection site reactions. Tizaro may be administered at any time of day, independently of meals. The approved initiation schedule begins with 2.5 mg once weekly for 4 weeks (tolerability initiation), followed by 5 mg once weekly as the first therapeutic dose for at least 4 weeks. Subsequent escalation steps 7.5 mg, 10 mg, 12.5 mg, and up to 15 mg are each maintained for a minimum of 4 weeks before advancing, if the treating endocrinologist determines further escalation is required. Store Tizaro pre-filled syringes refrigerated at 2°C to 8°C until use, or at room temperature up to 30°C for a maximum of 21 days if refrigeration is temporarily unavailable. Always confirm injection technique and dose escalation timing with the prescribing endocrinologist before commencing Tizaro therapy.

What are the side effects of Tizaro (Tirzepatide)?

The most common side effects of Tizaro (Tirzepatide) are gastrointestinal: nausea (12 to 18% at 5 mg), diarrhea (12 to 17%), vomiting (5 to 11%), and constipation (6 to 11%), predominantly occurring during dose initiation and escalation phases and generally transient. The mandatory 2.5 mg initiation dose protocol in the Tizaro dosing schedule is specifically designed to reduce the frequency and severity of gastrointestinal adverse effects during the first 4 weeks of treatment, and the 4-week minimum interval at each escalation step allows progressive GI adaptation. Injection site reactions (erythema, bruising, pain) are reported in approximately 3 to 7% of patients; rotating injection sites each week reduces their incidence. Hypoglycemia does not occur with Tizaro as monotherapy; hypoglycemia risk increases when Tizaro is combined with a sulfonylurea or basal insulin. Rare but serious adverse reactions include acute pancreatitis (discontinue Tizaro immediately if suspected) and severe hypersensitivity reactions including anaphylaxis and angioedema. Tizaro carries a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity data. Always discuss the full safety profile with the treating endocrinologist before and throughout Tizaro treatment.

Does Tizaro (Tirzepatide) cause weight loss?

Yes. Tizaro (Tirzepatide) produces clinically meaningful, dose-dependent body weight reductions in adults with type 2 diabetes, driven by its dual GIP and GLP-1 receptor agonism acting on hypothalamic satiety circuits to reduce appetite, gastric emptying delay reducing caloric absorption rate, and adipose tissue GIPR engagement modulating energy partitioning. In SURPASS-1 monotherapy (40 weeks), tirzepatide 5 mg, 10 mg, and 15 mg produced mean body weight reductions of 7.0 kg, 7.8 kg, and 9.5 kg respectively versus 0.7 kg with placebo. In SURPASS-2 versus semaglutide 1 mg (40 weeks, 1,879 patients), tirzepatide 5 mg, 10 mg, and 15 mg produced mean weight reductions of 7.6 kg, 9.3 kg, and 11.2 kg respectively, all significantly greater than semaglutide 1 mg at 5.7 kg (p<0.001). These weight reductions at the 10 mg, 12.5 mg, and 15 mg doses available only through Tizaro among Bangladeshi tirzepatide products are not achievable from competing products capped at 7.5 mg. For the full range of diabetes medicines at Mediaid Pharmacy available with worldwide shipping, browse the complete portfolio.

How does Tizaro (Tirzepatide) compare to semaglutide for type 2 diabetes?

Tizaro (Tirzepatide) and semaglutide (originator brand: Ozempic®) are both once-weekly subcutaneous injectable antidiabetic agents, but they act through different receptor mechanisms. Semaglutide is a monoagonist GLP-1 receptor agonist that activates only the GLP-1R. Tirzepatide is a dual GIP/GLP-1 receptor agonist (twincretin) that simultaneously activates both the GIPR and GLP-1R, adding a GIPR signaling arm that semaglutide cannot engage. In the SURPASS-2 head-to-head trial (1,879 adults with T2DM, 40 weeks), tirzepatide 5 mg, 10 mg, and 15 mg achieved HbA1c reductions of 1.94%, 2.10%, and 2.37% respectively and weight reductions of 7.6 kg, 9.3 kg, and 11.2 kg respectively, all superior to semaglutide 1 mg at 1.86% HbA1c reduction and 5.7 kg weight loss (p<0.001 at all doses). Tizaro’s availability across all six strengths including the 10 mg, 12.5 mg, and 15 mg doses where tirzepatide’s superiority over semaglutide is most pronounced is the key procurement advantage. The full selection of tirzepatide medicines at Mediaid Pharmacy is available for worldwide shipping; contact the team for pricing and stock availability.

Can I order Tizaro (Tirzepatide) online with worldwide shipping?

Yes. Mediaid Pharmacy supplies Ziska Pharmaceuticals Tizaro (Tirzepatide) pre-filled syringes, available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg strengths, to patients, diabetes specialist centers, endocrinology clinics, hospital pharmacy departments, and healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for pricing, current stock availability, and international delivery details for your country.

Order Tizaro (Tirzepatide) with Worldwide Shipping

Phone / WhatsApp / WeChat: +8801773428128  |  Email: info@mediaidpharmacy.com

Message on WhatsApp


Reviews

There are no reviews yet.

Be the first to review “Tizaro (Tirzepatide)”

Your email address will not be published. Required fields are marked *